WallStSmart
LYRA

Lyra Therapeutics Inc

NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY

$0.75
-5.71% today

Updated 2026-06-03

Market cap
$870050.00
P/E ratio
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
52W range
$0 – $34
Volume
0.0M

Lyra Therapeutics Inc (LYRA) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2018201920202021202220232024
Operating cash flow$-6.64M$-13.75M$-21.14M$-25.82M$-43.38M$-63.30M$-70.01M
Capital expenditures$37000.00$211000.00$1.77M$3.38M$164000.00$1.05M$2.34M
Depreciation
Stock-based comp$406000.00$244000.00$1.81M$2.77M$5.45M$5.89M$6.72M
Free cash flow$-6.68M$-13.96M$-22.92M$-29.20M$-43.55M$-64.35M$-72.35M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$64.78M

Frequently asked questions

What is Lyra Therapeutics Inc's revenue?

Lyra Therapeutics Inc's trailing twelve-month revenue is $600000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is LYRA?

In its most recent fiscal year, LYRA ran a gross margin of 100.00%, an operating margin of -6,280.83%, and a net margin of -6,090.94%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does LYRA generate?

LYRA produced $-72.35M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LYRA's balance sheet healthy?

LYRA holds $40.58M in cash and equivalents against — in long-term debt, on $11.59M of shareholder equity. That debt is best read against the cash flow the business throws off each year.